Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793005

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793005

Locally Advanced Pancreatic Cancer

PUBLISHED:
PAGES: 375 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Locally Advanced Pancreatic Cancer Market to Reach US$1.7 Billion by 2030

The global market for Locally Advanced Pancreatic Cancer estimated at US$966.3 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$750.1 Million by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$263.3 Million While China is Forecast to Grow at 14.8% CAGR

The Locally Advanced Pancreatic Cancer market in the U.S. is estimated at US$263.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$372.1 Million by the year 2030 trailing a CAGR of 14.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Locally Advanced Pancreatic Cancer Market - Key Trends & Drivers Summarized

Why Is Locally Advanced Pancreatic Cancer a Unique and Critical Challenge in Oncology?

Locally advanced pancreatic cancer, commonly referred to as LAPC, represents a complex and aggressive stage of pancreatic malignancy that has spread to nearby structures but has not yet metastasized to distant organs. This classification includes tumors that involve critical blood vessels, rendering them inoperable by traditional surgical methods at diagnosis. The challenge with LAPC lies in its silent progression and non-specific symptoms, which often leads to late detection and limited treatment windows. Despite not being metastatic, LAPC carries a high risk of systemic spread and poor overall prognosis, with five-year survival rates remaining dismally low. Its management requires a delicate balance of local disease control and systemic therapy, as the tumor often resists conventional treatment and progresses rapidly. The biology of pancreatic cancer itself is notoriously complex, marked by a dense stromal environment, limited immune cell infiltration, and intrinsic resistance to chemotherapy and radiotherapy. As a result, LAPC is often considered a transitional phase that requires multimodal therapeutic strategies combining chemotherapy, radiation, and in select cases, surgical re-evaluation after tumor downstaging. The emotional and physical toll on patients is significant, necessitating supportive care services alongside clinical intervention. Understanding LAPC’s role in the pancreatic cancer spectrum is critical to improving outcomes, as it represents a key juncture where aggressive, coordinated care may still influence survival and quality of life if applied effectively.

How Are Therapeutic Approaches Evolving for the Management of Locally Advanced Pancreatic Cancer?

Therapeutic strategies for locally advanced pancreatic cancer have evolved significantly in recent years, driven by advances in systemic therapy, targeted treatments, and improved diagnostic imaging. Historically, treatment focused primarily on palliative chemotherapy to slow disease progression, but this approach has shifted as multi-agent chemotherapy regimens such as FOLFIRINOX and gemcitabine-nab-paclitaxel have shown promise in shrinking tumors and improving survival. These regimens are now commonly used as first-line treatment to assess tumor response and evaluate potential conversion to resectable status. For patients who demonstrate a good response, the option of surgical exploration may become viable, offering a chance for curative resection that was previously unattainable. Radiation therapy, particularly with advanced modalities like stereotactic body radiotherapy (SBRT) and intensity-modulated radiation therapy (IMRT), is increasingly being used for local tumor control, either in combination with chemotherapy or as consolidation therapy after systemic treatment. Clinical trials are also exploring novel combinations of immunotherapy, anti-angiogenic agents, and personalized medicine based on molecular profiling of tumor tissue. The integration of genetic testing and biomarkers such as BRCA mutations and mismatch repair deficiency is guiding the use of targeted therapies, including PARP inhibitors, in select patient populations. Multidisciplinary care teams are essential in managing LAPC, involving oncologists, surgeons, radiologists, palliative care specialists, and nutritionists to provide comprehensive treatment plans. These evolving approaches are reshaping the treatment landscape and offering new hope for patients with a historically grim diagnosis.

What Patient-Centered and Diagnostic Trends Are Influencing the Management of LAPC?

The management of locally advanced pancreatic cancer is increasingly influenced by patient-centered care models and advances in diagnostic tools that enable more precise treatment planning. One major trend is the use of high-resolution imaging technologies such as contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans to assess tumor involvement with surrounding vasculature and determine resectability. These imaging modalities help guide treatment decisions and identify candidates for potential surgical conversion after systemic therapy. Another critical development is the use of endoscopic ultrasound (EUS) with fine-needle aspiration, which enables tissue sampling for histopathological diagnosis and genetic analysis, paving the way for individualized therapy. Patient-reported outcomes are also gaining prominence in evaluating treatment efficacy, as quality of life, symptom control, and functional status are considered alongside traditional survival metrics. Nutritional support and pain management are essential components of care, as weight loss, fatigue, and abdominal discomfort are common and debilitating symptoms in LAPC patients. Telemedicine is facilitating frequent follow-up and multidisciplinary consultations, especially in areas where access to specialty oncology care is limited. Psychological support and counseling are becoming integral, acknowledging the emotional strain associated with a diagnosis that often carries a limited prognosis. Shared decision-making frameworks are empowering patients to engage actively in their treatment choices, ensuring that interventions align with personal values and goals. These patient-centered and diagnostic trends are improving the delivery of care and contributing to more tailored, holistic approaches for managing LAPC.

What Are the Key Drivers Behind the Expanding Research and Clinical Focus on Locally Advanced Pancreatic Cancer?

The growth in research and clinical focus on locally advanced pancreatic cancer is driven by a combination of rising incidence rates, unmet medical needs, technological innovation, and growing awareness of the disease’s unique therapeutic window. As global rates of pancreatic cancer continue to increase, partly due to aging populations and lifestyle factors such as obesity and diabetes, the burden of LAPC is becoming more pronounced. The high mortality associated with this disease stage has prompted intensified efforts to find more effective treatments that can improve both survival and quality of life. Advances in genomics and biomarker research are enabling a more nuanced understanding of tumor biology, allowing researchers to identify molecular subtypes and therapeutic targets specific to LAPC. Pharmaceutical companies and academic institutions are increasingly investing in clinical trials that explore novel drug combinations, immune checkpoint inhibitors, and radio-sensitizing agents that may overcome the tumor’s natural resistance. Funding from global cancer organizations and patient advocacy groups is supporting awareness campaigns and research grants aimed at early diagnosis and treatment innovation. The emergence of adaptive clinical trial designs is allowing for more efficient evaluation of therapies in real time, accelerating the path to new standards of care. Artificial intelligence and machine learning tools are also being applied to diagnostic imaging and treatment planning, offering data-driven insights that could optimize patient outcomes. As collaborative networks grow and treatment protocols become more refined, the global focus on LAPC is creating momentum for improved clinical pathways and potentially transformative breakthroughs in the years ahead.

SCOPE OF STUDY:

The report analyzes the Locally Advanced Pancreatic Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery); Administration Route (Oral Administration, Injectable Administration, Other Administration Routes); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AB Science
  • Actuate Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Eli Lilly and Company
  • EXACT Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc (GSK)
  • Ipsen Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Limited
  • Oncolytics Biotech Inc.
  • Pfizer Inc.
  • RenovoRx
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verastem, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37299

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Locally Advanced Pancreatic Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Mortality and Limited Curative Options Throw the Spotlight on Intensified Research into LAPC Treatment Strategies
    • Advancements in Imaging and Early Detection Propel More Accurate Diagnosis and Staging of Locally Advanced Cases
    • Increasing Adoption of Neoadjuvant Therapies Strengthens Business Case for Multimodal Treatment in LAPC
    • Innovation in Radiation Techniques (SBRT, IMRT) Drives Targeted Local Control with Fewer Side Effects
    • Growth in Precision Oncology and Biomarker-Driven Therapies Spurs Demand for Molecular Profiling in LAPC Patients
    • Expanding Role of Immunotherapy and Checkpoint Inhibitors Generates Interest in Combination Regimens for LAPC
    • Rising Use of FOLFIRINOX and Modified Chemotherapy Protocols Enhances Progression-Free Survival Rates
    • Improved Access to Genetic Testing and Companion Diagnostics Supports Personalized Treatment Approaches
    • Development of Drug-Eluting Stents and Localized Drug Delivery Methods Opens New Avenues for Tumor Management
    • Global Increase in Pancreatic Cancer Incidence Sustains Clinical and Commercial Attention on LAPC
    • Healthcare System Investments in Cancer Centers of Excellence Boost Access to Multidisciplinary Care Models
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Locally Advanced Pancreatic Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • JAPAN
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CHINA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • EUROPE
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • FRANCE
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • GERMANY
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • INDIA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AFRICA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!